Citigroup Inc Sab Biotherapeutics, Inc. Transaction History

Citigroup Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.13 - $12.4 $18 - $1,798	-145 Reduced 22.69%	494 $0
Q2 2022 Aug 10, 2022	SELL	$1.11 - $3.46 $7,081 - $22,074	-6,380 Reduced 90.9%	639 $1,000
Q1 2022 May 12, 2022	BUY	$1.78 - $8.5 $10,202 - $48,722	5,732 Added 445.38%	7,019 $26,000
Q4 2021 Feb 10, 2022	BUY	$7.3 - $11.24 $9,395 - $14,465	1,287 New	1,287 $10,000

529K

Ticker SABS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,030,900
Market Cap $133M
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.